News
  Date Title View
Jul 25, 2016
BURLINGTON, Mass., July 25, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its second-quarter 2016 financial results on Wednesday, August 3, 2016, at 4:30 p.m. ET. The dial-in number for the conference call is ...
Jul 6, 2016
BURLINGTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- ...
Jun 8, 2016
BURLINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: ...
Jun 7, 2016
BURLINGTON, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- ...
May 26, 2016
BURLINGTON, Mass., May 26, 2016 (GLOBE NEWSWIRE) -- ...
May 12, 2016
Zilretta™, Flexion's non-opioid lead drug candidate (also known as FX006), completed pivotal Phase 2b and Phase 3 clinical registration trials, in patients with osteoarthritis (OA) of the kneePositive data from these trials, presented at the Osteoarthritis Research Society International (OARSI...
May 5, 2016
BURLINGTON, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first-quarter 2016 financial results on Thursday, May 12, 2016, at 4:30 p.m. ET. The dial-in number for the conference call is (855) 770-0022 for...
Apr 28, 2016
BURLINGTON, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported it has enrolled the first patient in a clinical trial to assess the effects of its lead drug candidate, Zilretta (also known as FX006), on blood glucose levels in approximately 36 adults with osteoarthritis (OA) of the k...
Apr 7, 2016
BURLINGTON, Mass., April 07, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 3:40 p.m. EDT in New York,...
Apr 4, 2016
Positive data from Zilretta Phase 2b and Phase 3 clinical trials demonstrate consistent efficacy across both studies with substantial and persistent pain reliefIn the Phase 3 trial Zilretta, in contrast to immediate-release triamcinolone acetonide (TCA), exceeds American Academy of Orthopedic Surgeons (AA...
FirstPrevious
3
... NextLast
= add release to Briefcase